Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Congenital cytogenetic abnormalities

Stanislawa Weremowicz, PhD
Section Editors
Charles J Lockwood, MD, MHCM
Louise Wilkins-Haug, MD, PhD
Helen V Firth, DM, FRCP, DCH
Deputy Editor
Elizabeth TePas, MD, MS


Chromosomal aberrations are due to a change in the normal chromosome number or a change in the structure of a chromosome. They may involve one, two, or more chromosomes and may involve only part of a chromosome or the whole chromosome. Congenital anomalies, growth deficiency, and intellectual disability are findings often present in individuals with chromosome abnormalities, although some cytogenetic aberrations have little to no clinical effect. Rapid progress in human cytogenetics has demonstrated a causal relationship between various chromosomal abnormalities and their phenotypic manifestations. In addition, the specific chromosomal etiologies of a wide variety of syndromes have been established. (See "Chromosomal translocations, deletions, and inversions" and "Overview of genetic variation" and "Genomic disorders: An overview".)

This topic reviews the most common chromosomal abnormalities and discusses when to refer a patient/parent for a genetic evaluation. Diseases caused by point mutations and other small genetic defects are discussed elsewhere. (See "Microdeletion syndromes (chromosomes 1 to 11)" and "Microdeletion syndromes (chromosomes 12 to 22)" and "Microduplication syndromes" and "Sex chromosome abnormalities" and "Down syndrome: Clinical features and diagnosis".)


Fifteen percent of clinically recognized pregnancies result in fetal death [1]. Cytogenetic abnormalities are more common in spontaneous abortions (50 percent of fetal deaths <20 weeks) than in stillbirths (6 to 13 percent of fetal deaths ≥20 weeks). A 1998 multicenter survey of 103,069 live births in the United States identified major chromosomal abnormalities in 1 in 140 live births (table 1) [2]. However, the incidence of chromosomal abnormalities is dependent upon the sample and population studied and the type of diagnostic testing used. As an example, the incidence is lower among live births than among abortuses, second trimester fetuses, or stillbirths. Trisomy 21 (Down syndrome) remains the most common chromosomal abnormality among liveborn infants [3-5].

Diagnosis of chromosomal abnormalities by conventional karyotyping has several limitations compared with a subsequently developed technique based upon microarray analysis [1,6,7]. As an example, analysis of macerated fetuses and nonviable tissues from spontaneous abortions and stillbirths has low yield. In addition, chromosome banding techniques can only detect major structural abnormalities. Array comparative genomic hybridization (aCGH) can detect smaller copy number variations (eg, DNA gains and losses) and has a higher yield when performed on fetal tissue from pregnancy losses. Thus, aCGH may become the preferred type of testing to analyze fetal loss as it becomes more readily available, less costly, and easier to perform. The use of aCGH in prenatal diagnosis of chromosomal abnormalities and postnatal evaluation of pregnancy loss is discussed in detail separately. (See "Use of chromosomal microarray in obstetrics" and "Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Detecting cytogenetic abnormalities' and "Genomic disorders: An overview".)

Total versus live birth prevalence — Estimates of total and live-birth prevalence of trisomy 21 (Down syndrome) and other trisomies vary depending upon demographics, race, year of data collection, regional differences in prenatal screening and pregnancy termination, and maternal age. A comparison of amniocentesis and liveborn data regarding the incidence of trisomy 21 (Down syndrome) is shown in the table (table 2). The maternal age-specific rate of trisomy 21, as well as other chromosomal abnormalities, is approximately 30 percent higher when diagnosed in the early second trimester by amniocenteses than when diagnosed after birth. These differences can be explained, in part, by an increased late spontaneous fetal loss rate (after the early second trimester) for fetuses with chromosomal abnormalities [8,9].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 24, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Reddy UM, Page GP, Saade GR. The role of DNA microarrays in the evaluation of fetal death. Prenat Diagn 2012; 32:371.
  2. Hsu LYF. Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Genetic disorders and the fetus, 4th ed, Milunsky A (Ed), The Johns Hopkins University Press, Baltimore 1998. p.179.
  3. Centers for Disease Control and Prevention (CDC). Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2006; 54:1301.
  4. Collins VR, Muggli EE, Riley M, et al. Is Down syndrome a disappearing birth defect? J Pediatr 2008; 152:20.
  5. Weijerman ME, van Furth AM, Vonk Noordegraaf A, et al. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr 2008; 152:15.
  6. Warren JE, Turok DK, Maxwell TM, et al. Array comparative genomic hybridization for genetic evaluation of fetal loss between 10 and 20 weeks of gestation. Obstet Gynecol 2009; 114:1093.
  7. Shaffer LG, Dabell MP, Fisher AJ, et al. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat Diagn 2012; 32:976.
  8. Hook EB. Spontaneous deaths of fetuses with chromosomal abnormalities diagnosed prenatally. N Engl J Med 1978; 299:1036.
  9. Hook EB. Chromosome abnormalities and spontaneous fetal death following amniocentesis: further data and associations with maternal age. Am J Hum Genet 1983; 35:110.
  10. Loane M, Morris JK, Addor MC, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 2013; 21:27.
  11. Savva GM, Morris JK, Mutton DE, Alberman E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006; 26:499.
  12. Egan JF, Smith K, Timms D, et al. Demographic differences in Down syndrome livebirths in the US from 1989 to 2006. Prenat Diagn 2011; 31:389.
  13. Kratzer PG, Golbus MS, Schonberg SA, et al. Cytogenetic evidence for enhanced selective miscarriage of trisomy 21 pregnancies with advancing maternal age. Am J Med Genet 1992; 44:657.
  14. Hassold T, Chiu D. Maternal age-specific rates of numerical chromosome abnormalities with special reference to trisomy. Hum Genet 1985; 70:11.
  15. Warburton D, Kline J, Stein Z, et al. Cytogenetic abnormalities in spontaneous abortions of recognized conception. In: Perinatal genetics diagnosis and treatment, Porter IH, Willey A (Eds), Academic Press, New York 1986. p.133.
  16. Wolstenholme J. An audit of trisomy 16 in man. Prenat Diagn 1995; 15:109.
  17. Langlois S, Yong PJ, Yong SL, et al. Postnatal follow-up of prenatally diagnosed trisomy 16 mosaicism. Prenat Diagn 2006; 26:548.
  18. Yong PJ, Barrett IJ, Kalousek DK, Robinson WP. Clinical aspects, prenatal diagnosis, and pathogenesis of trisomy 16 mosaicism. J Med Genet 2003; 40:175.
  19. Korteweg FJ, Bouman K, Erwich JJ, et al. Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. Obstet Gynecol 2008; 111:865.
  20. Alberman ED, Creasy MR. Frequency of chromosomal abnormalities in miscarriages and perinatal deaths. J Med Genet 1977; 14:313.
  21. Staebler M, Donner C, Van Regemorter N, et al. Should determination of the karyotype be systematic for all malformations detected by obstetrical ultrasound? Prenat Diagn 2005; 25:567.
  22. Michalski ST, Porter J, Pauli RM. Costs and consequences of comprehensive stillbirth assessment. Am J Obstet Gynecol 2002; 186:1027.
  23. Jones KL. Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006.
  24. Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet 2001; 17:83.
  25. Sheets KB, Crissman BG, Feist CD, et al. Practice guidelines for communicating a prenatal or postnatal diagnosis of Down syndrome: recommendations of the national society of genetic counselors. J Genet Couns 2011; 20:432.
  26. Chandra N, Cyril C, Lakshminarayana P, et al. Cytogenetic evaluation of Down syndrome: A review of 1020 referral cases. Int J Hum Genet 2010; 10:87.
  27. Antonarakis SE, Avramopoulos D, Blouin JL, et al. Mitotic errors in somatic cells cause trisomy 21 in about 4.5% of cases and are not associated with advanced maternal age. Nat Genet 1993; 3:146.
  28. Alberman E, Mutton D, Morris JK. Cytological and epidemiological findings in trisomies 13, 18, and 21: England and Wales 2004-2009. Am J Med Genet A 2012; 158A:1145.
  29. Antonarakis SE. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down Syndrome Collaborative Group. N Engl J Med 1991; 324:872.
  30. Antonarakis SE. 10 years of Genomics, chromosome 21, and Down syndrome. Genomics 1998; 51:1.
  31. Muller F, Rebiffé M, Taillandier A, et al. Parental origin of the extra chromosome in prenatally diagnosed fetal trisomy 21. Hum Genet 2000; 106:340.
  32. Antonarakis SE, Adelsberger PA, Petersen MB, et al. Analysis of DNA polymorphisms suggests that most de novo dup(21q) chromosomes in patients with Down syndrome are isochromosomes and not translocations. Am J Hum Genet 1990; 47:968.
  33. Epstein CJ, Korenberg JR, Annerén G, et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 1991; 49:207.
  34. EDWARDS JH, HARNDEN DG, CAMERON AH, et al. A new trisomic syndrome. Lancet 1960; 1:787.
  35. Kosho T, Nakamura T, Kawame H, et al. Neonatal management of trisomy 18: clinical details of 24 patients receiving intensive treatment. Am J Med Genet A 2006; 140:937.
  36. Lin HY, Lin SP, Chen YJ, et al. Clinical characteristics and survival of trisomy 18 in a medical center in Taipei, 1988-2004. Am J Med Genet A 2006; 140:945.
  37. Pont SJ, Robbins JM, Bird TM, et al. Congenital malformations among liveborn infants with trisomies 18 and 13. Am J Med Genet A 2006; 140:1749.
  38. Bruns D, Campbell E. Twenty-two survivors over the age of 1 year with full trisomy 18: presenting and current medical conditions. Am J Med Genet A 2014; 164A:610.
  39. Lakovschek IC, Streubel B, Ulm B. Natural outcome of trisomy 13, trisomy 18, and triploidy after prenatal diagnosis. Am J Med Genet A 2011; 155A:2626.
  40. Burke AL, Field K, Morrison JJ. Natural history of fetal trisomy 18 after prenatal diagnosis. Arch Dis Child Fetal Neonatal Ed 2013; 98:F152.
  41. Rasmussen SA, Wong LY, Yang Q, et al. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 2003; 111:777.
  42. Vendola C, Canfield M, Daiger SP, et al. Survival of Texas infants born with trisomies 21, 18, and 13. Am J Med Genet A 2010; 152A:360.
  43. Nelson KE, Hexem KR, Feudtner C. Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States. Pediatrics 2012; 129:869.
  44. Nelson KE, Rosella LC, Mahant S, Guttmann A. Survival and Surgical Interventions for Children With Trisomy 13 and 18. JAMA 2016; 316:420.
  45. PATAU K, SMITH DW, THERMAN E, et al. Multiple congenital anomaly caused by an extra autosome. Lancet 1960; 1:790.
  46. Wyllie JP, Wright MJ, Burn J, Hunter S. Natural history of trisomy 13. Arch Dis Child 1994; 71:343.
  47. Tolmie JL. Down syndrome and other autosomal trisomies. In: Emery and Rimoin's principles and practice of medical genetics, 3rd ed, Rimoin DL, Connor JM, Pyeritz RE (Eds), Churchill Livingstone, 1996. p.925.
  48. Petry P, Polli JB, Mattos VF, et al. Clinical features and prognosis of a sample of patients with trisomy 13 (Patau syndrome) from Brazil. Am J Med Genet A 2013; 161A:1278.
  49. Jones KL, Grandal Jones M, Del Campo L. Smith's Recognizable Patterns of Human Malformation, 7th ed., Elsevier Saunders, Philadelphia 2013.
  50. Springett A, Wellesley D, Greenlees R, et al. Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000-2011. Am J Med Genet A 2015; 167A:3062.
  51. Peroos S, Forsythe E, Pugh JH, et al. Longevity and Patau syndrome: what determines survival? BMJ Case Rep 2012; 2012.
  52. Tsukada K, Imataka G, Suzumura H, Arisaka O. Better prognosis in newborns with trisomy 13 who received intensive treatments: a retrospective study of 16 patients. Cell Biochem Biophys 2012; 63:191.
  53. Bruns D. Birth history, physical characteristics, and medical conditions in long-term survivors with full trisomy 13. Am J Med Genet A 2011; 155A:2634.
  54. Riccardi VM. Trisomy 8: an international study of 70 patients. Birth Defects Orig Artic Ser 1977; 13:171.
  55. Chen CP, Chen M, Pan YJ, et al. Prenatal diagnosis of mosaic trisomy 8: clinical report and literature review. Taiwan J Obstet Gynecol 2011; 50:331.
  56. Karadima G, Bugge M, Nicolaidis P, et al. Origin of nondisjunction in trisomy 8 and trisomy 8 mosaicism. Eur J Hum Genet 1998; 6:432.
  57. Schinzel A. Trisomy 8 mosaicism. In: Catalogue of unbalanced chromosome aberrations in man, 2nd ed, Schinzel A (Ed), Water de Gunter, GmbH&Co, Berlin 2001. p.384.
  58. Miller K, Arslan-Kirchner A, Schulze B, et al. Mosaicism in trisomy 8: phenotype differences according to tissular repartition of normal and trisomic clones. Ann Genet 1997; 40:181.
  59. van Haelst MM, Van Opstal D, Lindhout D, Los FJ. Management of prenatally detected trisomy 8 mosaicism. Prenat Diagn 2001; 21:1075.
  60. Hsu LY, Yu MT, Neu RL, et al. Rare trisomy mosaicism diagnosed in amniocytes, involving an autosome other than chromosomes 13, 18, 20, and 21: karyotype/phenotype correlations. Prenat Diagn 1997; 17:201.
  61. Schinzel A. Trisomy 8 and trisomy 9 are distinctly different clinical entities. Am J Med Genet 1993; 46:603.
  62. Gün I, Akpak YK, Müngen E. Common sonographic characteristics of trisomy 8 mosaicism. Int J Gynaecol Obstet 2012; 119:85.
  63. Katz-Fuller B, Raff R, Eggermann T, et al. Longitudinal study in patient with trisomy 8 mosaicism: Cytogenetic and molecular-genetic investigations over a period of eleven years. Int J Hum Genet 2002; 2:101.
  64. Webb AL, Wolstenholme J, Evans J, et al. Prenatal diagnosis of mosaic trisomy 8 with investigations of the extent and origin of trisomic cells. Prenat Diagn 1998; 18:737.
  65. James RS, Jacobs PA. Molecular studies of the aetiology of trisomy 8 in spontaneous abortions and the liveborn population. Hum Genet 1996; 97:283.
  66. Danesino C, Pasquali F, Dellavecchia C, et al. Constitutional trisomy 8 mosaicism: mechanism of origin, phenotype variability, and risk of malignancies. Am J Med Genet 1998; 80:540.
  67. Machin GA, Crolla JA. Chromosome constitution of 500 infants dying during the perinatal period. With an appendix concerning other genetic disorders among these infants. Humangenetik 1974; 23:183.
  68. Arnold GL, Kirby RS, Stern TP, Sawyer JR. Trisomy 9: review and report of two new cases. Am J Med Genet 1995; 56:252.
  69. Wooldridge J, Zunich J. Trisomy 9 syndrome: report of a case with Crohn disease and review of the literature. Am J Med Genet 1995; 56:258.
  70. Mantagos S, McReynolds JW, Seashore MR, Breg WR. Complete trisomy 9 in two liveborn infants. J Med Genet 1981; 18:377.
  71. Kannan TP, Hemlatha S, Ankathil R, Zilfalil BA. Clinical manifestations in trisomy 9. Indian J Pediatr 2009; 76:745.
  72. Bruns D. Presenting physical characteristics, medical conditions, and developmental status of long-term survivors with trisomy 9 mosaicism. Am J Med Genet A 2011; 155A:1033.
  73. Zen PR, Rosa RF, Rosa RC, et al. New report of two patients with mosaic trisomy 9 presenting unusual features and longer survival. Sao Paulo Med J 2011; 129:428.
  74. Slater HR, Ralph A, Daniel A, et al. A case of maternal uniparental disomy of chromosome 9 diagnosed prenatally and the related problem of residual trisomy. Prenat Diagn 2000; 20:930.
  75. Fujimoto A, Allanson J, Crowe CA, et al. Natural history of mosaic trisomy 14 syndrome. Am J Med Genet 1992; 44:189.
  76. von Sneidern E, Lacassie Y. Is trisomy 14 mosaic a clinically recognizable syndrome?--case report and review. Am J Med Genet A 2008; 146A:1609.
  77. Shinawi M, Shao L, Jeng LJ, et al. Low-level mosaicism of trisomy 14: phenotypic and molecular characterization. Am J Med Genet A 2008; 146A:1395.
  78. Merritt TA, Natarajan G. Trisomy 14 Mosaicism: a case without evidence of neurodevelopmental delay and a review of the literature. Am J Perinatol 2007; 24:563.
  79. Hsu LY, Shapiro LR, Gertner M, et al. Trisomy 22: a clinical entity. J Pediatr 1971; 79:12.
  80. Bacino CA, Schreck R, Fischel-Ghodsian N, et al. Clinical and molecular studies in full trisomy 22: further delineation of the phenotype and review of the literature. Am J Med Genet 1995; 56:359.
  81. Mokate T, Leask K, Mehta S, et al. Non-mosaic trisomy 22: a report of 2 cases. Prenat Diagn 2006; 26:962.
  82. Tinkle BT, Walker ME, Blough-Pfau RI, et al. Unexpected survival in a case of prenatally diagnosed non-mosaic trisomy 22: Clinical report and review of the natural history. Am J Med Genet A 2003; 118A:90.
  83. Tonni G, Ventura A, Pattacini P, et al. Complex cardiac defect, bowing of lower limbs and multiple anomalies in trisomy 22. Ultrasound, post-mortem CT findings with necropsy confirmation. Fetal Pediatr Pathol 2012; 31:439.
  84. Mazza V, Latella S, Fenu V, et al. Prenatal diagnosis and postnatal follow-up of a child with mosaic trisomy 22 with several levels of mosaicism in different tissues. J Obstet Gynaecol Res 2010; 36:1116.
  85. Leclercq S, Baron X, Jacquemont ML, et al. Mosaic trisomy 22: five new cases with variable outcomes. Implications for genetic counselling and clinical management. Prenat Diagn 2010; 30:168.
  86. McWeeney DT, Munné S, Miller RC, et al. Pregnancy complicated by triploidy: a comparison of the three karyotypes. Am J Perinatol 2009; 26:641.
  87. Yilmaz Z, Sahin FI, Tarim E, Kuscu E. Triploidies in first and second trimesters of pregnancies in Turkey. BJMG 2007; 10:71.
  88. McFadden DE, Kalousek DK. Two different phenotypes of fetuses with chromosomal triploidy: correlation with parental origin of the extra haploid set. Am J Med Genet 1991; 38:535.
  89. Miny P, Koppers B, Dworniczak B, et al. Parental origin of the extra haploid chromosome set in triploidies diagnosed prenatally. Am J Med Genet 1995; 57:102.
  90. Hsu LYF. Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Genetic disorders and the fetus, 4th ed, Milansky A (Ed), The Johns Hopkins University Press, Baltimore 1998. p.179.
  91. Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 1991; 87:81.
  92. Blennow E, Bui TH, Kristoffersson U, et al. Swedish survey on extra structurally abnormal chromosomes in 39 105 consecutive prenatal diagnoses: prevalence and characterization by fluorescence in situ hybridization. Prenat Diagn 1994; 14:1019.
  93. Huang B, Solomon S, Thangavelu M, et al. Supernumerary marker chromosomes detected in 100,000 prenatal diagnoses: molecular cytogenetic studies and clinical significance. Prenat Diagn 2006; 26:1142.
  94. Malvestiti F, De Toffol S, Grimi B, et al. De novo small supernumerary marker chromosomes detected on 143,000 consecutive prenatal diagnoses: chromosomal distribution, frequencies, and characterization combining molecular cytogenetics approaches. Prenat Diagn 2014; 34:460.
  95. Graf MD, Christ L, Mascarello JT, et al. Redefining the risks of prenatally ascertained supernumerary marker chromosomes: a collaborative study. J Med Genet 2006; 43:660.
  96. Baldwin EL, May LF, Justice AN, et al. Mechanisms and consequences of small supernumerary marker chromosomes: from Barbara McClintock to modern genetic-counseling issues. Am J Hum Genet 2008; 82:398.
  97. Huang B, Crolla JA, Christian SL, et al. Refined molecular characterization of the breakpoints in small inv dup(15) chromosomes. Hum Genet 1997; 99:11.
  98. Hou JW, Wang TR. Unusual features in children with inv dup(15) supernumerary marker: a study of genotype-phenotype correlation in Taiwan. Eur J Pediatr 1998; 157:122.
  99. Robinson WP, Wagstaff J, Bernasconi F, et al. Uniparental disomy explains the occurrence of the Angelman or Prader-Willi syndrome in patients with an additional small inv dup(15) chromosome. J Med Genet 1993; 30:756.
  100. Gorla N, Slavutsky I, Lisanti J, et al. Cytogenetic characterization of an extra structurally abnormal chromosome associated with severe mental retardation: inv dup (15) (q13). Hereditas 1998; 129:1.
  101. Battaglia A. The inv dup (15) or idic (15) syndrome (Tetrasomy 15q). Orphanet J Rare Dis 2008; 3:30.
  102. Spinner NB, Zackai E, Cheng SD, Knoll JH. Supernumerary inv dup(15) in a patient with Angelman syndrome and a deletion of 15q11-q13. Am J Med Genet 1995; 57:61.
  103. Crolla JA, Youings SA, Ennis S, Jacobs PA. Supernumerary marker chromosomes in man: parental origin, mosaicism and maternal age revisited. Eur J Hum Genet 2005; 13:154.
  104. Kotzot D, Bundscherer G, Bernasconi F, et al. Isochromosome 18p results from maternal meiosis II nondisjunction. Eur J Hum Genet 1996; 4:168.
  105. Eggermann T, Schubert R, Engels H, et al. Formation of supernumerary euchromatic short arm isochromosomes: parent and cell stage of origin in new cases and review of the literature. Ann Genet 1999; 42:75.
  106. Swingle HM, Ringdahl J, Mraz R, et al. Behavioral management of a long-term survivor with tetrasomy 18p. Am J Med Genet A 2006; 140:276.
  107. Sebold C, Roeder E, Zimmerman M, et al. Tetrasomy 18p: report of the molecular and clinical findings of 43 individuals. Am J Med Genet A 2010; 152A:2164.
  108. Abeliovich D, Dagan J, Levy A, et al. Isochromosome 18p in a mother and her child. Am J Med Genet 1993; 46:392.
  109. Boyle J, Sangha K, Dill F, et al. Grandmaternal origin of an isochromosome 18p present in two maternal half-sisters. Am J Med Genet 2001; 101:65.
  110. Vogel I, Lyngbye T, Nielsen A, et al. Pallister-Killian syndrome in a girl with mild developmental delay and mosaicism for hexasomy 12p. Am J Med Genet A 2009; 149A:510.
  111. Yeung A, Francis D, Giouzeppos O, Amor DJ. Pallister-Killian syndrome caused by mosaicism for a supernumerary ring chromosome 12p. Am J Med Genet A 2009; 149A:505.
  112. Giordano L, Viri M, Borgatti R, et al. Seizures and EEG patterns in Pallister-Killian syndrome: 13 new Italian patients. Eur J Paediatr Neurol 2012; 16:636.
  113. Filloux FM, Carey JC, Krantz ID, et al. Occurrence and clinical features of epileptic and non-epileptic paroxysmal events in five children with Pallister-Killian syndrome. Eur J Med Genet 2012; 55:367.
  114. McDermid HE, Duncan AM, Brasch KR, et al. Characterization of the supernumerary chromosome in cat eye syndrome. Science 1986; 232:646.
  115. Mears AJ, el-Shanti H, Murray JC, et al. Minute supernumerary ring chromosome 22 associated with cat eye syndrome: further delineation of the critical region. Am J Hum Genet 1995; 57:667.
  116. Berends MJ, Tan-Sindhunata G, Leegte B, van Essen AJ. Phenotypic variability of Cat-Eye syndrome. Genet Couns 2001; 12:23.
  117. Rosias PR, Sijstermans JM, Theunissen PM, et al. Phenotypic variability of the cat eye syndrome. Case report and review of the literature. Genet Couns 2001; 12:273.
  118. Rosa RF, Mombach R, Zen PR, et al. Clinical characteristics of a sample of patients with cat eye syndrome. Rev Assoc Med Bras (1992) 2010; 56:462.
  119. Jacobs PA, Browne C, Gregson N, et al. Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. J Med Genet 1992; 29:103.
  120. Niebuhr E. The Cri du Chat syndrome: epidemiology, cytogenetics, and clinical features. Hum Genet 1978; 44:227.
  121. Cerruti Mainardi P. Cri du Chat syndrome. Orphanet J Rare Dis 2006; 1:33.
  122. Overhauser J, Huang X, Gersh M, et al. Molecular and phenotypic mapping of the short arm of chromosome 5: sublocalization of the critical region for the cri-du-chat syndrome. Hum Mol Genet 1994; 3:247.
  123. Church DM, Bengtsson U, Nielsen KV, et al. Molecular definition of deletions of different segments of distal 5p that result in distinct phenotypic features. Am J Hum Genet 1995; 56:1162.
  124. Gersh M, Goodart SA, Pasztor LM, et al. Evidence for a distinct region causing a cat-like cry in patients with 5p deletions. Am J Hum Genet 1995; 56:1404.
  126. Mainardi PC, Perfumo C, Calì A, et al. Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-phenotype correlation. J Med Genet 2001; 38:151.
  127. Van Buggenhout GJ, Pijkels E, Holvoet M, et al. Cri du chat syndrome: changing phenotype in older patients. Am J Med Genet 2000; 90:203.
  128. Marinescu RC, Mainardi PC, Collins MR, et al. Growth charts for cri-du-chat syndrome: an international collaborative study. Am J Med Genet 2000; 94:153.
  129. Budisteanu M, Arghir A, Chirieac SM, et al. 18q deletion syndrome - A case report. Maedica (Buchar) 2010; 5:135.
  131. Fryns JP, Logghe N, van Eygen M, van den Berghe H. 18q- syndrome in mother and daughter. Eur J Pediatr 1979; 130:189.
  132. Silverman GA, Schneider SS, Massa HF, et al. The 18q- syndrome: analysis of chromosomes by bivariate flow karyotyping and the PCR reveals a successive set of deletion breakpoints within 18q21.2-q22.2. Am J Hum Genet 1995; 56:926.
  133. Strathdee G, Sutherland R, Jonsson JJ, et al. Molecular characterization of patients with 18q23 deletions. Am J Hum Genet 1997; 60:860.
  134. Safi KH, Fathalla BM. Inflammatory and noninflammatory arthropathy in patients with 18q deletion syndrome. J Clin Rheumatol 2012; 18:36.
  135. Lomenick JP, Smith WJ, Rose SR. Autoimmune thyroiditis in 18q deletion syndrome. J Pediatr 2005; 147:541.
  136. Jayarajan V, Swan IR, Patton MA. Hearing impairment in 18q deletion syndrome. J Laryngol Otol 2000; 114:963.
  137. Ghidoni PD, Hale DE, Cody JD, et al. Growth hormone deficiency associated in the 18q deletion syndrome. Am J Med Genet 1997; 69:7.
  138. Feenstra I, Vissers LE, Orsel M, et al. Genotype-phenotype mapping of chromosome 18q deletions by high-resolution array CGH: an update of the phenotypic map. Am J Med Genet A 2007; 143A:1858.
  139. Brkanac Z, Cody JD, Leach RJ, DuPont BR. Identification of cryptic rearrangements in patients with 18q- deletion syndrome. Am J Hum Genet 1998; 62:1500.
  140. Cody JD, Hale DE, Brkanac Z, et al. Growth hormone insufficiency associated with haploinsufficiency at 18q23. Am J Med Genet 1997; 71:420.
  141. Linnankivi TT, Autti TH, Pihko SH, et al. 18q-syndrome: brain MRI shows poor differentiation of gray and white matter on T2-weighted images. J Magn Reson Imaging 2003; 18:414.
  142. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001; 81:871.
  143. Cody JD, Semrud-Clikeman M, Hardies LJ, et al. Growth hormone benefits children with 18q deletions. Am J Med Genet A 2005; 137:9.